You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

ADDERALL XR 20 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Adderall Xr 20, and what generic alternatives are available?

Adderall Xr 20 is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in ADDERALL XR 20 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADDERALL XR 20?
  • What are the global sales for ADDERALL XR 20?
  • What is Average Wholesale Price for ADDERALL XR 20?
Drug patent expirations by year for ADDERALL XR 20
Recent Clinical Trials for ADDERALL XR 20

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Boston Children's HospitalPhase 1
Eva SzigethyPhase 4
The Beckwith InstitutePhase 4

See all ADDERALL XR 20 clinical trials

Pharmacology for ADDERALL XR 20

US Patents and Regulatory Information for ADDERALL XR 20

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa ADDERALL XR 20 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-002 Oct 11, 2001 AB1 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ADDERALL XR 20

International Patents for ADDERALL XR 20

See the table below for patents covering ADDERALL XR 20 around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1123087 SYSTEME D'ADMINISTRATION DE MEDICAMENTS PAR DOSES PULSEES PAR VOIE ORALE (ORAL PULSED DOSE DRUG DELIVERY SYSTEM) ⤷  Sign Up
Austria 427101 ⤷  Sign Up
Germany 69940673 ⤷  Sign Up
Spain 2323910 ⤷  Sign Up
Canada 2348090 SYSTEME D'ADMINISTRATION DE MEDICAMENTS PAR DOSES PULSEES PAR VOIE ORALE (ORAL PULSED DOSE DRUG DELIVERY SYSTEM) ⤷  Sign Up
European Patent Office 1977736 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.